Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study
Open accessThe DOI matches its Crossref record; 58 of the 64 references it cites were found in a registry or an index; 38 of the 73 sources its claims cite were checked for support.
Abstract
Several studies of the effects on cognition of selective serotonin reuptake inhibitors (SSRI), administered either acutely or sub-chronically in healthy volunteers, have found changes in learning and reinforcement outcomes. In contrast, to our knowledge, there have been no studies of chronic effects of escitalopram on cognition in healthy volunteers. This is important in view of its clinical use in major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). Consequently, we aimed to investigate the chronic effect of the SSRI, escitalopram, on measures of 'cold' cognition (including inhibition, cognitive flexibility, memory) and 'hot cognition' including decision-making and particularly reinforcement learning. The study, conducted at the University of Copenhagen between May 2020 and October 2021, used a double-blind placebo-controlled design with 66 healthy volunteers, semi-randomised to receive either 20 mg of escitalopram (n = 32) or placebo (n = 34), balanced for age, sex and intelligence quotient (IQ) for at least 21 days. Questionnaires, neuropsychological tests and serum escitalopram measures were taken. We analysed group differences on the cognitive measures using linear regression models as well as innovative hierarchical Bayesian modelling of the Probabilistic Reversal Learning (PRL) task. The novel and important finding was that escitalopram reduced reinforcement sensitivity compared to placebo on both the Sequential Model-Based/Model-Free task and the PRL task. We found no other significant group differences on 'cold' or 'hot' cognition. These findings demonstrate that serotonin reuptake inhibition is involved in reinforcement learning in healthy individuals. Lower reinforcement sensitivity in response to chronic SSRI administration may reflect the 'blunting' effect often reported by patients with MDD treated with SSRIs. Trial Registration: NCT04239339 .
Overview
CoChat Summary
TL;DR
In healthy volunteers, chronic escitalopram (20 mg daily for at least 21 days) reduced reinforcement sensitivity on two independent reinforcement-learning tasks compared with placebo, without affecting other ‘cold’ or ‘hot’ cognitive measures. The authors suggest this may relate to the clinical ‘blunting’ effect reported by patients on chronic SSRIs.
Key findings
- Escitalopram reduced reinforcement sensitivity in hierarchical Bayesian modelling of the Probabilistic Reversal Learning task: mean difference = −2.77 [90% HDI, −5.29 to −0.40].
- Escitalopram also reduced reinforcement sensitivity on the Sequential Model-Based/Model-Free task: Reward × Group interaction estimated coefficient = −0.34, p < 0.01, 95% CI [−0.57 to −0.11].
- There were no significant group differences for reward learning rate, punishment learning rate, or stimulus stickiness in the PRL model, and no significant group differences on any ‘hot’ or ‘cold’ cognitive outcomes that survived multiple comparisons.
- The escitalopram group had significantly higher dysfunction on CSFQ-14 orgasm/ejaculation dimension 5 and phase 3: t(42.25) = 2.68, p = 0.01, Cohen’s d = 0.68; there was no sex difference for the change score.
Methods
- Double-blind, placebo-controlled, semi-randomised study with 66 healthy volunteers: 32 received escitalopram 20 mg daily and 34 received placebo for at least 21 days (escitalopram mean(s.d.) = 26.06(2.78) days; placebo = 26.09(3.29) days); participants were matched for age, sex, and IQ.
- Participants completed questionnaires and an extensive neuropsychological battery assessing ‘cold’ and ‘hot’ cognition, including Probabilistic Reversal Learning, Sequential Model-Based/Model-Free, stop-signal/go-no-go, set-shifting, memory, attention, decision-making, social cognition, and emotion tasks; serum escitalopram was measured by UPLC-MS/MS.
- Group comparisons used linear regression models with age, sex, IQ, and baseline reaction time as covariates, with Benjamini-Hochberg FDR q = 0.05; PRL data were analysed with hierarchical Bayesian reinforcement-learning models, and MBMF data with generalised linear mixed-effects regression.
Limitations
- The paper states there was a significant difference in guessing group allocation: 53% of the escitalopram group correctly guessed escitalopram, whereas 15.6% of the placebo group guessed escitalopram (χ2(1, N = 65) = 10.46, p = 0.01); the authors note the escitalopram group was at chance level and argue results are unlikely affected given the lack of cognitive changes and specificity of the effect.
- The authors state they cannot rule out that neuroplasticity effects might be greater with a longer duration of escitalopram, and that there is no reliable non-invasive way to determine interstitial serotonin concentrations in humans, making interpretation inferential.
- The authors note the sample was cognitively high-performing (average IQ > 110) healthy volunteers, so effects may differ from patients with MDD; they also report that exact sample sizes varied slightly across tasks due to technical issues and time constraints.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
27 Valid · 1 Not valid · 12 Not checked · 32 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lower reinforcement sensitivity in response to chronic SSRI administration may reflect the ‘blunting’ effect often reported by patients with MDD treated with SSRIs.”
§ Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study > Abstract
What the sources say
- Not checked — no full text of the sourcecites [40] Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: a clinical review. J Psychiatr Pract. 2004;10:196–9. source
- Partly supportedcites [41] Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195:211–7. sourceExperimental — accuracy not yet measured
The Background and Discussion report that some people taking SSRIs describe emotional blunting, and that participants attributed reduced emotional intensity to their medication. The Discussion also says the study cannot establish how common these effects are or draw robust causal conclusions. It does not test whether lower reinforcement sensitivity reflects emotional blunting, so the proposed link and the word “often” go beyond this source. (LLM, conf=0.86)
- Not matchedcites [42] Marazziti D, Mucci F, Tripodi B, Carbone MG, Muscarella A, Falaschi V, et al. Emotional blunting, cognitive impairment, bone fractures, and bleeding as possible side effects of long-term use of SSRIs. Clin Neuropsychiatry. 2019;16:75.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Currently, only a few studies have examined SSRIs administered sub-chronically, over approximately 7 days [24, 25].”
§ Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study > Introduction
What the sources say
- Not checked — no full text of the sourcecites [24] Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004;161:1256–63. source
- Supportedcites [25] Michely J, Eldar E, Erdman A, Martin IM, Dolan RJ. Serotonin modulates asymmetric learning from reward and punishment in healthy human volunteers. Commun Biol. 2022;5:1–9. source
The Methods (Pharmacological procedure; page unavailable) describe daily administration of the SSRI citalopram for seven consecutive days, making this paper an example of the studies cited. The Introduction also says SSRI studies of learning asymmetries had mainly used single-dose administration or clinical populations, though that observation is specific to learning asymmetries. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Specifically, participants receiving 7 days of SSRI had lower neural processing of both rewarding and aversive stimuli [43].”
§ Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study > Discussion > Reinforcement behaviour
What the sources say
- Supportedcites [43] McCabe C, Mishor Z, Cowen PJ, Harmer CJ. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry. 2010;67:439–45. source
The Discussion states that seven days of SSRI treatment diminished neural processing of both rewarding and aversive stimuli. The Methods identify the participants as healthy volunteers assigned to citalopram, reboxetine, or placebo. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, there is some evidence that the neuroplasticity effects of SSRIs emerge only after more chronic administration (14–21 days) [29, 30].”
§ Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study > Introduction
What the sources say
- Partly supportedcites [29] Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:7539–47. sourceExperimental — accuracy not yet measured
In “Chronic antidepressant drug treatments increase the expression of BDNF and trkB mRNA” (page not provided), sertraline, an SSRI, increased these markers in rat hippocampus after 21 days, whereas acute treatment did not significantly increase BDNF mRNA. The paper does not test a 14-day course or establish when the effects first emerge, and its measured outcome is gene expression rather than neuroplasticity more broadly. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [30] De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, et al. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience. 2004;128:597–604. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Patients’ often report experiencing a ‘blunting’ effect [40–42].”
§ Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study > Discussion > Reinforcement behaviour
What the sources say
- Not checked — no full text of the sourcecites [40] Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: a clinical review. J Psychiatr Pract. 2004;10:196–9. source
- Supportedcites [41] Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195:211–7. source
The introduction says that some people taking SSRIs mention a ‘blunting of emotions.’ In ‘General effects on all emotions,’ most participants described their emotions as flattened or dulled, supporting the paraphrase for patients taking SSRIs. (LLM, conf=0.92)
- Not matchedcites [42] Marazziti D, Mucci F, Tripodi B, Carbone MG, Muscarella A, Falaschi V, et al. Emotional blunting, cognitive impairment, bone fractures, and bleeding as possible side effects of long-term use of SSRIs. Clin Neuropsychiatry. 2019;16:75.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
17 more claims
Create a free account to see all 72 claims and to verify the 2 references still open.
- Probably not a substantial claim. 38
- It may state two separate claims as one. 25
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, escitalopram, while effective in alleviating depressive symptoms, has shown limited evidence of cognitive enhancement [9].”
From Efficacy of Vortioxetine Versus Escitalopram on the Cognitive Profile of Patients With Depressive Disorder: A Comparative Study (2025) · cites this paper as [9]
Experimental — accuracy not yet measured
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Consistentt(63) = 0.04reported p = .97 · recomputed p = .968
“t(63) = 0.04, p = .97”
- Consistentχ²(1) = 10.46reported p = .01 · recomputed p = .001
“χ2 (1, N = 65) = 10.46, p = .01”
The paper prints p at a floor (such as p < .001)
- Consistentt(42.25) = 2.68reported p = .01 · recomputed p = .010
“t (42.25) = 2.68, p = .01”
- Consistentt(42.25) = 2.68reported p = .01 · recomputed p = .010
“t(42.25) = 2.68, p = .01”
- Consistentt(64) = -1.15reported p = .25 · recomputed p = .254
“t(64) = −1.15, p = .25”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
(1998) · PubMed · Cited by 10,216
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 2×
“In addition, acute administration of SSRIs does not seem to affect neuroplasticity, which does occur when administered chronically [29, 30].”
BackgroundFu, C. H. Y., Williams, S. C. R., Cleare, A. J., Brammer, M. J., Walsh, N. D., Kim, J., Andrew, C. M., Pich, E. M., Williams, P. M., Reed, L. J., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.9.877 · Cited by 775
Serotoninergic regulation of emotional and behavioural control processes
Cools, R., Roberts, A. C., & Robbins, T. W. (2008) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2007.10.011 · Cited by 656 · cited 1×
“INTRODUCTION Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter implicated in several cognitive and affective brain functions [1].”
BackgroundSelf-citationCognitive Inflexibility After Prefrontal Serotonin Depletion
Clarke, H. F., Dalley, J. W., Crofts, H. S., Robbins, T. W., & Roberts, A. C. (2004) · Science · doi:10.1126/science.1094987 · Cited by 632
Self-citationHow do antidepressants work? New perspectives for refining future treatment approaches
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616
Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573 · cited 3×
“One study showed that response inhibition improved with SSRI administration [20], whereas another showed no effect [19].”
BackgroundSelf-citationHarmer, C. J., Shelley, N. C., Cowen, P. J., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.7.1256 · Cited by 554
Harmer, C. J., Goodwin, G. M., & Cowen, P. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051193 · Cited by 542
Cited by
The Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression
Smith, A. L. W., Harmer, C. J., Cowen, P. J., & Murphy, S. E. (2023) · CNS Drugs · doi:10.1007/s40263-023-01014-7 · Cited by 78
Johansen, A., Armand, S., Plavén-Sigray, P., Nasser, A., Ozenne, B., Petersen, I. N., Keller, S. H., Madsen, J., Beliveau, V., Møller, K., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02285-8 · Cited by 53
Self-citationHung, L. Y., Alves, N. D., Colle, A. D., Talati, A., Najjar, S. A., Bouchard, V., Gillet, V., Tong, Y., Huang, Z., Browning, K. N., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.11.012 · Cited by 57
Luo, Q., Kanen, J. W., Bari, A., Skandali, N., Langley, C., Knudsen, G. M., Alsiö, J., Phillips, B. U., Sahakian, B. J., Cardinal, R. N., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01762-6 · Cited by 29
Self-citationThe serotonin hypothesis of depression: both long discarded and still supported?
Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., Plöderl, M., & Horowitz, M. A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02094-z · Cited by 33
Metadata
- Authors
- Langley, C., Armand, S., Luo, Q., Savulich, G., Segerberg, T., Søndergaard, A., Pedersen, E. B., Svart, N., Overgaard-Hansen, O., Johansen, A., Borgsted, C., Cardinal, R. N., Robbins, T. W., Stenbæk, D. S., Knudsen, G. M., & Sahakian, B. J.
- Affiliations
- University of Cambridge (GB)
- University of Copenhagen (DK)
- Fudan University (CN)
- Corresponding author
- Langley, Christelle
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2023-01-23
- Volume
- 48
- Issue
- 4
- Pages
- 664-670
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC9938113
- OpenAlex
- W4317715429
- Cited by
- 58
- References
- 64
- Citations by year
- 2026: 16 · 2025: 19 · 2024: 16 · 2023: 7
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Apollo
- Funders
- Lundbeckfonden
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- escitalopram, selective serotonin reuptake inhibitors, long-term drug effects, reinforcement learning, reinforcement sensitivity, probabilistic reversal learning, decision-making, cognitive flexibility, inhibition, memory, serotonin reuptake inhibition, major depressive disorder, obsessive-compulsive disorder
- MeSH terms
- Escitalopram, Bayes Theorem, Major Depressive Disorder, Double-Blind Method, Humans, Infant, Newborn, Citalopram, Selective Serotonin Reuptake Inhibitors, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study. https://app.cochat.ai/papers/10.1038/s41386-022-01523-x
- The paper
- Langley, C., Armand, S., Luo, Q., Savulich, G., Segerberg, T., Søndergaard, A., Pedersen, E. B., Svart, N., Overgaard-Hansen, O., Johansen, A., Borgsted, C., Cardinal, R. N., Robbins, T. W., Stenbæk, D. S., Knudsen, G. M., & Sahakian, B. J. (2023). Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study. Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01523-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.